Today, Lilly/BI announced first-ever news in diabetes: a major clinical trial on Jardiance, an SGLT-2 inhibitor pill for type 2 diabetes, has been proven to improve heart safety in patients at high risk for heart problems.
Hopes are high: Headlines about “blockbuster” and “game-changer” diet drugs emerge alongside grim reports about the obesity epidemic, which affects about 36% of adults in the United States. The latest medication to join the pack is Saxenda, the name for liraglutide, which the Food and Drug Administration approved in December.
The American Association of Clinical Endocrinologists (AACE) is exploring the reportedly high incidences of diabetic ketoacidosis (DKA) in people taking SGLT2 inhibitors. The investigation will take place at a conference the autumn.
The results showed a lower dementia incidence with pioglitazone with cumulative long-term use of pioglitazone reducing the dementia risk by 47% (RR=0.53, p=0.029) when compared to non-diabetics.
Diabetic ketoacidosis is a complication of diabetes that occurs when the body produces elevated levels of acidic compounds called ketones, often due to a lack of effective insulin action, which can lead to hospitalization, coma, and even death if left untreated.
Taking the medication metformin hydrochloride was associated with reduced risk of developing the sight-threatening disease open-angle glaucoma in people with diabetes, according to a study published online by JAMA Ophthalmology.
A certain class of type 2 diabetes drugs can lead to a life-threatening condition called ketoacidosis, the U.S. Food and Drug Administration warns.
The FDA just held a public meeting to discuss the results from two major heart safety trials conducted on the DPP-4 inhibitor drugs Onglyza and Nesina. Both trials suggested that the drugs do not increase the risk of cardiovascular events, such as heart attacks and strokes. Following a long day of testimonies, the FDA committee […]
Few doctors are prescribing a low-cost drug that has been proven effective in preventing the onset of diabetes, according to a UCLA study. The study, published in the peer-reviewed journal Annals of Internal Medicine, found that only 3.7 percent of U.S. adults with pre-diabetes were prescribed metformin during a recent three-year period.
Food and drug interactions are much more common than most people realize. Many people on prescription drugs probably already know it’s a bad idea to drink alcohol, which can interfere with many medications. But foods as seemingly innocuous as sausage and cheddar cheese can cause dangerous side effects for those taking certain types of antidepressants.
New research published in Diabetologia (the journal of the European Association for the Study of Diabetes) shows that use of statins is associated with a 46% increase in the risk of developing diabetes, even after adjustment for confounding factors.
On March 23, Lilly/BI announced the US launch of Glyxambi at pharmacies nationwide. This comes two months after FDA approval and represents the first SGLT-2 inhibitor/DPP-4 inhibitor fixed dose combination drug available in the US. Its main benefit is combining two different diabetes drugs into a single pill (in this case, Tradjenta and Jardiance) with […]
Glyxambi combines empagliflozin, a sodium glucose cotransporter-2 inhibitor that blocks the absorption of excess glucose by the kidneys so it is released through urine, and linagliptin, a DPP-4 inhibitor that increases the production of insulin by the beta cells of the pancreas while reducing the amount of glucose produced by the liver.
This was the finding of a comprehensive analysis of clinical trials covering more than 95,000 patients reported in The Lancet Diabetes and Endocrinology. The study was also presented at the 64th Annual Scientific Session of the American College of Cardiology in San Diego, CA, earlier this week.
Are the FDA guidelines for metformin use really as current as they should be?
In previous studies, metformin has been shown to decrease the risk of cancer in type 2 diabetes. A recent meta-analysis showed a 34% reduction in the incidence of any cancer and a 33% reduction in cancer mortality; however, the studies are prone to bias and failed to confirm the results of observational studies.
The painkiller tramadol (brand names Ultram, ConZip, Ultram ER) is linked to an increased risk of hospitalization for hypoglycemia (low blood sugar) in people both with and without diabetes, according to a recent study by scientists at McGill University in Montreal. The use of this medicine has grown in recent years, with retailers dispensing 43.8 […]
The new drug, Xigduo XR, is a once-daily tablet that merges the recently approved diabetes drug dapagliflozin with the popular drug metformin.
There is some level of risk of CVD events that would result in a positive trade-off of benefit and risk for the use of aspirin, but the precise level of risk is remains uncertain
There have been a number of new developments in the treatment of type 2 diabetes, and a question often asked is whether some of the type 2 therapies might be beneficial for people with type 1 diabetes.